重组抗人CD19单抗(B43)流式 | Syd Labs PA007423.h1Fs
重组抗人CD19单克隆抗体，人IgG1 Fc Silent Kappa（克隆号 B43，Syd Labs货号：PA007423.h1Fs）是用哺乳动物细胞生产的重组抗体，适用于流式细胞术（FC）和免疫组织化学-冷冻（IHC-F）等研究，纯度>95%。其不变区为人Human IgG1 kappa (hIgG1或h1)，可与重组人IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007423.h1Fs |
|---|---|
| 产品名称 | 重组抗人CD19单抗(B43)流式 | Syd Labs PA007423.h1Fs |
| 英文名 | Non-conjugated Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Human IgG1 Fc Silent Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | B-淋巴细胞抗原 CD19，分化簇 19，B-淋巴细胞表面抗原 B4，T-细胞表面抗原 Leu-12，CVID3 |
| 概述 | Syd Labs提供重组小鼠IgG2a同型对照抗体和重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | B43 |
| 同种型 | 人 IgG1 kappa |
| 特异性 | 该重组 B43 抗体与人 CD19 蛋白特异性结合 |
| 免疫源 | 重组抗人 CD19 单克隆抗体 (克隆：B43)在哺乳动物细胞中产生 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，含0.09%叠氮化钠 |
| 偶联 | 非偶联 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 非偶联重组抗人CD19单克隆抗体，人IgG1 Fc Silent Kappa(克隆号B43) 用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 12个月，保存在2 至 8°C。 请勿冻结。 |
| 注意事项 | PA007423.h1Fs Syd Labs提供重组小鼠IgG2a同型对照抗体和重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | 流式细胞术（FC）和免疫组织化学-冷冻（IHC-F）。 |
文献
抗人CD19单克隆抗体(克隆号B43)，非偶联重组，人IgG1 Fc Silent Kappa（Non-conjugated Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Human IgG1 Fc Silent Kappa，货号：PA007423.h1Fs Syd Labs）
B43抗体可结合人CD19蛋白，该蛋白是一种表达于包括人浆细胞在内的所有B系细胞表面的跨膜蛋白。CD19在人B细胞中发挥两大核心作用：一是作为接头蛋白将细胞质信号蛋白招募至细胞膜，二是在CD19/CD21复合物中发挥作用，以降低B细胞受体信号通路的激活阈值。CD19是B淋巴细胞发育及淋巴瘤诊断的重要生物标志物，同时也可用作白血病免疫治疗的靶点。
抗人CD19单抗(B43)部分参考文献:
1.Fluorescent labeling in semi-solid medium for selection of mammalian cells secreting high-levels of recombinant proteins
Caron, A. W., et al. BMC Biotechnol. 2009 May;9(42):42. PMID: 19432976
“The light chain of the B43 antibody (anti-human CD19) was replaced in the pMPGB43k expression vector, which carries an enhanced CMV enhancer/promoter and a hygromycin resistance gene, to construct a new vector for recombinant protein expression. The B43 antibody (anti-human CD19 mAb) coding sequence was modified via PCR and cloned into the PmeI site of pMPGB34k, with a BamHI site added for further modifications. The study also isolated the IGF-1 coding sequence from murine cDNA for constructing pMPG-IGF-E5.”
2.Downregulation of major histocompatibility complex class I molecules by Kaposi’s sarcoma-associated herpesvirus K3 and K5 proteins
Ishido, S., et al. J Virol. 2000 Jun;74(11):5300-9. PMID: 10799607
“The B43 antibody (anti-human CD19) was used alongside W6/32 (MHC class I), RPA-T8 (CD8), M-A712 (transferrin receptor), and TU39 (MHC class II) for fluorescence-activated cell sorting and confocal immunofluorescence analyses. K3 and K5 proteins specifically downregulated MHC class I without affecting MHC class II, immunoglobulin M, or CD19 surface levels, as confirmed by these antibodies.”
3.Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma
Myers, D. E., et al. Leuk Lymphoma. 1998 Apr;29(3-4):329-38. PMID: 9684930
“The B43(anti-human CD19 antibody)-genistein immunoconjugate was manufactured at large scale for clinical trials in leukemia and lymphoma. The B43 antibody was purified from ascites fluid using protein A affinity chromatography, and its conjugation to genistein was optimized for high yield. Flow cytometry confirmed effective binding of B43-genistein to CD19+ leukemic cells, with cytotoxicity tested against leukemia cell lines.”
4.Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys
Kreitman, R. J., et al. Clin Cancer Res. 1997 Mar;3(3):325-37. PMID: 9815689
“The B43(anti-human CD19)-pokeweed antiviral protein (PAP) immunotoxin was evaluated in cynomolgus monkeys for pharmacokinetics, immunogenicity, and toxicity. B43-PAP, constructed by linking the anti-CD19 monoclonal antibody B43 to PAP, killed >99.9% of primary leukemic progenitor cells from B-lineage ALL patients. The study revealed dose-limiting renal and cardiac toxicity in mice and severe renal tubular necrosis in monkeys.”
5.Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells
Myers, D. E., et al. Proc Natl Acad Sci U S A. 1995 Oct;92(21):9575-9. PMID: 7568175
“The B43 monoclonal antibody (anti-human CD19 mAb) was used to cross-link membrane-associated CD19, activating the LYN kinase signaling pathway and inducing apoptosis in B-lineage lymphoma cells in a p53- and Bcl-2-independent manner. The CD19-LYN complex was immunoprecipitated using B43 antibody, and flow cytometry confirmed high-level CD19 expression on lymphoma cells.”